Liraglutide (LEADER trial), semaglutide (SUSTAIN-6), and dulaglutide (REWIND trial) have shown significant reductions in major adverse cardiovascular events (MACE) in patients with established cardiovascular disease or multiple cardiovascular risk factors
Neuropsychiatr Dis Treat (2019), 164957
Glucagon-like peptide-1 Receptor Agonists (GLP-1RA) medications have emerged as a novel treatment opportunity for HS patients
Rather than ranking platforms against each other - pricing and medication options are changing faster than any static comparison can stay current - here's a practical framework for evaluating any two platforms you're seriously considering side by side
Sermorelin makes short, sleep-aligned pulses while CJC-1295 gives a longer, steady signal, and combining them under medical supervision may support recovery, lean muscle, sleep, and daily energy when paired with training and good nutrition
What treatments are available to improve diabetes and its complications through the inhibition of ferroptosis
